Aerpio Comes to the 'Rescue' With HPTP-beta Drug for DME

Aragon Pharmaceuticals Inc. parlayed its successful Phase II results in prostate cancer to a new financing round worth $50 million supported by existing investors and led by new investor venBio. The funds will support advancement of ARN-509 in castration-resistant prostate cancer (CRPC).

Aragon has raised a total of $88 million in 2012, having closed a $42 million Series C in March. (See BioWorld Today, March 6, 2012.)